2023-05-15T12:09:06-05:00 2022-12-31 390974031 WEGNER CPAS LLP 419 N LEE ST ALEXANDRIA VA 223142301 990 2022-01-01 821199380 GLOBAL COALITION FOR ADAPTIVE RESEARCH INC GLOB 6172996471 700 LARKSPUR LANDING CIRCLE 199 LARKSPUR CA 949391754 RACHAEL COLEMAN CFO/COO 6172996471 2023-05-12 1 RACHAEL COLEMAN 999009999 0 GLENN MILLER CPA P00086726 7035190990 2023-05-12 3 AAL1 IAL1 2022 2023-04-26 12:10:37Z MEREDITH BUXTON 700 LARKSPUR LANDING CIRCLE 199 LARKSPUR CA 949391754 35373148 0 X GCARESEARCH.ORG X 2017 MD TO LEAD THE DEVELOPMENT AND ONGOING MANAGEMENT OF CLINICAL TRIAL PLATFORMS TO ACCELERATE THE DISCOVERY AND DEVELOPMENT OF CURES FOR PATIENTS WITH RARE AND DEADLY DISEASES. 8 5 31 39 0 0 504130 543271 38210063 34345933 5504 483944 0 0 38719697 35373148 0 0 0 0 2873252 4724320 0 0 0 16329913 19359003 19203165 24083323 19516532 11289825 40740875 59575227 13880420 21752254 26860455 37822973 OUR MISSION IS TO LEAD THE DEVELOPMENT AND ONGOING MANAGEMENT OF CLINICAL TRIAL PLATFORMS TO ACCELERATE THE DISCOVERY AND DEVELOPMENT OF CURES FOR PATIENTS WITH RARE AND DEADLY DISEASES. 0 0 17703368 0 31521012 GBM AGILE (GLIOBLASTOMA ADAPTIVE GLOBAL INNOVATIVE LEARNING ENVIRONMENT) IS UNIQUELY DESIGNED AS A LONG-STANDING PLATFORM WITH THE ABILITY TO TEST MULTIPLE THERAPIES AT THE SAME TIME AGAINST A COMMON CONTROL (OR STANDARD OF CARE). THE PURPOSE IS TO EVALUATE MULTIPLE INVESTIGATIONAL TREATMENTS FOR EITHER NEWLY DIAGNOSED OR RECURRENT GLIOBLASTOMA TO DETERMINE IF ANY OF THESE STUDY TREATMENT(S) IMPROVE OVERALL SURVIVAL AS COMPARED TO STANDARD TREATMENTS. 3270151 0 2331100 THE OBJECTIVE OF REMAP-COVID IS TO REDUCE MORTALITY AND MORBIDITY IN PATIENTS HOSPITALIZED WITH COVID-19 INFECTION BY QUICKLY GENERATING NEW EVIDENCE ON AVAILABLE AND NOVEL TREATMENTS. THROUGH PARTNERSHIPS WITH ACADEMIA, INDUSTRY AND MULTIPLE HEALTHCARE SYSTEMS, GCAR IS SPONSORING REMAP-COVID IN THE US WITH THE UNIVERSITY OF PITTSBURGH SERVING AS THE US REGIONAL COORDINATING CENTER FOR REMAP-CAP. 2018549 0 493821 CONSULTING, IN-DEVELOPMENT, AND SHORTER DURATION PROGRAMS IN OTHER RARE AND DEADLY DISEASE AREAS. 22992068 1 1 0 0 0 0 0 0 0 0 0 1 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 15 0 31 1 0 0 0 0 0 0 0 0 0 0 0 0 X 8 5 0 0 1 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 CA X RACHAEL COLEMAN 6108889275 700 LARKSPUR LANDING CIRCLE STE 199 LARKSPUR CA 949391754 BRIAN ALEXANDER MD MPH DIRECTOR 1.00 X 0 0 0 FARAMARZ YOUSEFZADEH JD LLM CHAIRMAN OF THE BOARD 1.00 X 0 0 0 GARY GORDON MD PHD SENIOR MEDICAL ADVISOR AND DIRECTOR 4.00 X 84000 0 0 JOHN FRISHKOPF MMS DIRECTOR 1.00 X 0 0 0 SUJUAN BA PHD SECRETARY (THRU MID-DEC)/DIRECTOR 1.00 X 0 0 0 TIMOTHY CLOUGHESY MD CHIEF MEDICAL OFFICER AND DIRECTOR 8.00 X X 120000 0 0 WK ALFRED YUNG MD INVESTIGATOR CHINA-CHAIR, AGILE & DIRECTOR 1.00 X 48360 0 0 WEBSTER CAVENEE PHD DIRECTOR 1.00 X 0 0 0 MATTHEW VIVA ASSOC DIRECTOR LEGAL/SECRETARY 40.00 X 225992 0 19681 MEREDITH BUXTON CHIEF EXECUTIVE OFFICER & PRESIDENT 40.00 X 700000 0 48256 RACHAEL COLEMAN CFO/COO 40.00 X 351567 0 4635 ASHLEY POWELL EXECUTIVE DIRECTOR OF TRIAL OPS 40.00 X 274663 0 17060 ROBERT MURRAY CHIEF BUSINESS OFFICER 40.00 X 359326 0 11062 APOORVA NELLI SENIOR CLINICAL SCIENTIST 40.00 X 177074 0 18299 RACHEL ROSENSTEIN SISSON SR DIRECTOR OF ADMINISTRATION 40.00 X 172500 0 14174 SARAH UNTCH ASSOC DIRECTOR TRIAL OPS 40.00 X 195011 0 25961 TRACEY ROBERTS ASSOC DIRECTOR, CLINICAL OPERATIONS 40.00 X 190000 0 19835 ADAM JOHNSON SR MANAGER CLIN DATA MANAGEMENT 40.00 X 140563 0 25083 3039056 0 204046 13 0 1 0 IQVIA 1700 PERIMETER PARK DR MORRISVILLE NC 27560 CLINICAL RESEARCH 12693182 BERRY CONSULTANTS 3345 BEE CAVES RD STE 201 AUSTIN TX 78746 STATISTICAL DATA 606987 MEDIDATA 350 HUDSON ST 9TH FLOOR NEW YORK NY 10014 CLINICAL RESEARCH 382571 WILSON SONSINI 650 PAGE MILL RD PALO ALTO CA 94304 LEGAL SERVICES 187973 MONALEE SCHULTZMRS CONSULTING 315 VIA SAN SEBASTIAN REDONDO BEACH CA 90277 LEGAL SERVICES 136796 7 543271 543271 TRIAL REVENUE 541700 34345933 34345933 34345933 483944 483944 35373148 34345933 0 483944 X 2264602 2002135 262467 1972617 1759648 212969 64617 57128 7489 194891 172303 22588 227593 201215 26378 88405 39810 48595 38752 38752 7108 7108 18685932 18629731 56201 24342 1285 23057 38293 2038 36255 107683 5686 101997 5272 278 4994 99653 70555 29098 32961 19240 13721 230602 31016 199586 24083323 22992068 1091255 0 5668875 7218662 30360174 0 4551658 3062438 160168 2146734 0 26178251 0 20969142 40740875 59575227 3469813 7592023 8910607 12660231 1500000 1500000 13880420 21752254 X 26860455 37822973 26860455 37822973 40740875 59575227 11289825 -327307 0 X 0 1 X 1 0 X 1525750 662857 365772 504130 543271 3601780 1525750 662857 365772 504130 543271 3601780 425397 3176383 2303 5866 5504 483944 497617 4099397 100297424 0.77480 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 MONEY MARKET FUNDS 20969142 F 20969142 REFUNDABLE ADVANCE 1500000 1500000 35209823 -327307 171090 -7108 -163325 35373148 0 35373148 24247305 171090 171090 24076215 7108 7108 24083323 PART XI, LINE 2D - OTHER ADJUSTMENTS: INVESTMENT FEES -7,108. X X 0 0 0 0 0 0 0 0 0 MEREDITH BUXTON CHIEF EXECUTIVE OFFICER & PRESIDENT 450000 0 250000 0 0 0 12750 0 35506 0 748256 0 0 0 ROBERT MURRAY CHIEF BUSINESS OFFICER 249326 0 110000 0 0 0 9567 0 1495 0 370388 0 0 0 RACHAEL COLEMAN CFO/COO 251567 0 100000 0 0 0 3325 0 1310 0 356202 0 0 0 ASHLEY POWELL EXECUTIVE DIRECTOR OF TRIAL OPS 199663 0 75000 0 0 0 7662 0 9398 0 291723 0 0 0 MATTHEW VIVA ASSOC DIRECTOR LEGAL/SECRETARY 170992 0 55000 0 0 0 5526 0 14155 0 245673 0 0 0 SARAH UNTCH ASSOC DIRECTOR TRIAL OPS 150011 0 45000 0 0 0 6400 0 19561 0 220972 0 0 0 TRACEY ROBERTS ASSOC DIRECTOR, CLINICAL OPERATIONS 160000 0 30000 0 0 0 6400 0 13435 0 209835 0 0 0 APOORVA NELLI SENIOR CLINICAL SCIENTIST 153303 0 23771 0 0 0 6132 0 12167 0 195373 0 0 0 RACHEL ROSENSTEIN SISSON SR DIRECTOR OF ADMINISTRATION 150000 0 22500 0 0 0 4250 0 9924 0 186674 0 0 0 ADAM JOHNSON SR MANAGER CLIN DATA MANAGEMENT 105563 0 35000 0 0 0 4720 0 20363 0 165646 0 0 0 FORM 990, PART VI, SECTION A, LINE 4 THE ORGANIZATION AMENDED ITS BYLAWS TO RECOGNIZE THE CHANGE IN CORPORATE NAME FROM AGILE RESEARCH FOUNDATION, INC. TO GLOBAL COALITION FOR ADAPTIVE RESEARCH, INC.; INTRODUCED STAGGERED TERMS FOR CURRENT AND FUTURE BOARD MEMBERS; MADE ADMINISTRATIVE CHANGES TO THE AUTHORITIES DELEGATED TO THE CEO AND ADDED DESCRIPTIONS OF THE OFFICES OF THE COO, CMO AND CSO.; REMOVE THE CHIEF INTERNATIONAL DEVELOPMENT OFFICER AS AN OFFICER POSITION; AND INDICATE THAT THE CHIEF FINANCIAL OFFICER SERVES AS TREASURER. FORM 990, PART VI, SECTION B, LINE 11B CHAIRMAN OF THE BOARD REVIEWS WITH ACCOUNTING FIRM. ONCE FORM IS COMPLETE, FORM IS REVIEWED WITH THE ENTIRE BOARD. FORM 990, PART VI, SECTION B, LINE 12C EACH DIRECTOR AND OFFICER IS REQUIRED TO SUBMIT AN UPDATED CONFLICT OF INTEREST STATEMENT ON AN ANNUAL BASIS. TO THE EXTENT THAT RELATIONSHIPS ARE IDENTIFIED VIA THESE STATEMENTS AND OTHER INFORMATION, THE INDIVIDUAL'S CONSTITUENT RECORD IN THE COMPANY DATABASE IS UPDATED TO INCLUDE THIS INFORMATION, FACILITATING PERIODIC QUERIES, AS NECESSARY. ANY BOARD MEMBER WITH A CONFLICT MUST IDENTIFY THE CONFLICT AT ANY BOARD MEETING WHERE THE CONFLICT IS RELEVANT. THE MEMBER CANNOT BE PRESENT AT ANY PART OF THE MEETING WHERE THE RELEVANT TOPIC IS DISCUSSED OR VOTED ON. THE MEMBER CANNOT BE COUNTED FOR A QUORUM. FORM 990, PART VI, SECTION B, LINE 15 THE BOARD OF DIRECTORS IS RESPONSIBLE FOR THE REVIEW AND APPROVAL OF TOP LEVEL EXECUTIVE MANAGEMENT COMPENSATION ANNUALLY. INDEPENDENT PROFESSIONAL EXPERTS ARE CALLED UPON FOR HIGHER LEVEL POSITIONS AND ASSIST IN ESTABLISHING EXECUTIVE SALARIES IN THE COMPETITIVE MARKETPLACE. SALARIES IN BOTH FOR PROFIT AND NOT FOR PROFIT ORGANIZATIONS ARE EVALUATED IN ORDER TO ATTRACT THE MOST TALENTED PERSONNEL. INFORMATION IS GATHERED, ANALYZED AND DISCUSSED WITH THE INTENT ON ENSURING THAT THE EXECUTIVE COMPENSATION PROGRAM FALLS WITHIN A REASONABLE RANGE OF COMPETITIVE PRACTICES FOR COMPARABLE POSITIONS AMONG SIMILARLY SITUATED ORGANIZATIONS. THE REVIEW INCLUDES INCENTIVE PLANS AND ALL FRINGE BENEFITS AS WELL AS BASE SALARY ARRANGEMENTS. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST. FORM 990, PART IX, LINE 11G TRIAL EXPENSES: PROGRAM SERVICE EXPENSES 18,629,731. MANAGEMENT AND GENERAL EXPENSES 56,201. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 18,685,932.